Cao Xiang-shan, Gu Wei-ying, Chen Zi-xing, Hu Shao-yan, He Jun, Cen Jian-nong
The Third Affiliated Hospital of Soochow University, The First People's Hospital of Changzhou, Changzhou 213003, China.
Zhonghua Nei Ke Za Zhi. 2007 Apr;46(4):277-9.
To investigate the clinical significance of Wilms tumor gene (WT1) expression levels in the bone marrow (BM) of chronic myelogenous leukemia patients.
Real-time quantitative retroversion polymerase chain reaction (RQ-RT-PCR) method was established for detecting WT1 and GAPDH expression levels in the BM of 109 CML and 23 non-leukemic patients with Light Cycler. Normalized WT1 expression level (WT1(N)) was determined as a ratio between WT1 and GAPDH expression times 10(4).
The median expression levels of WT1(N) in 23 CML patients of accelerate phase (CML-AP) and 22 CML patients of blast crisis (CML-BC) were statistically higher than those of 64 CML patients of chronic phase (CML-CP) and 23 non-leukemic controls (103.71 and 129.44 vs 3.44 and 1.47). No statistic differences were found between the CML-CP group and control group, nor between the CML-AP group and CML-BC group. Furthermore, the WT1(N) levels were correlated to the BCR/ABL fusion gene expression levels. Dynamic change of WT1(N) levels in 7 CML patients before or after allogeneic bone marrow transplantation showed that WT1 expression levels could predict relapse of leukemia.
WT1 expression levels in CML patients in accelerate phase or blast crisis were strikingly higher than those in non-leukemic patients or CML patients in chronic phase, in whom WT1 expression was undetectable or showed low expression. WT1 gene could be an useful marker for detecting MRD and evaluating therapeutic efficacy in CML.
探讨慢性粒细胞白血病患者骨髓中威尔姆斯瘤基因（WT1）表达水平的临床意义。
建立实时定量逆转录聚合酶链反应（RQ-RT-PCR）法，用Light Cycler检测109例慢性粒细胞白血病患者和23例非白血病患者骨髓中WT1和甘油醛-3-磷酸脱氢酶（GAPDH）的表达水平。将WT1标准化表达水平（WT1(N)）定义为WT1与GAPDH表达量之比乘以10(4)。
23例加速期慢性粒细胞白血病（CML-AP）患者和22例急变期慢性粒细胞白血病（CML-BC）患者的WT1(N)中位表达水平在统计学上高于64例慢性期慢性粒细胞白血病（CML-CP）患者和23例非白血病对照者（分别为103.71和129.44，对比3.44和1.47）。CML-CP组与对照组之间、CML-AP组与CML-BC组之间均未发现统计学差异。此外，WT1(N)水平与BCR/ABL融合基因表达水平相关。7例慢性粒细胞白血病患者异基因骨髓移植前后WT1(N)水平的动态变化表明，WT1表达水平可预测白血病复发。
加速期或急变期慢性粒细胞白血病患者的WT1表达水平显著高于非白血病患者或慢性期慢性粒细胞患者，后者WT1表达不可检测或呈低表达。WT1基因可能是检测慢性粒细胞白血病微小残留病（MRD）和评估治疗疗效的有用标志物。
